Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,132.62 -6.64 -0.21%
FTSE 100 6,571.83 -12.34 -0.19%
DAX 9,313.52 -4.30 -0.05%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Intercept to Present at Upcoming Healthcare Conferences



Intercept to Present at Upcoming Healthcare Conferences

NEW YORK, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.
(Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused
on the development and commercialization of novel bile acid therapeutics to
treat chronic liver and intestinal diseases, today announced that Mark
Pruzanski, M.D., President and Chief Executive Officer, will present at the
following investor conferences:

  * RBC Capital Markets Healthcare Conference on February 26, 2014, at 11:00
    a.m. ET, at The New York Palace hotel in New York, NY
  * Cowen & Company's 34th Annual Health Care Conference on March 3, 2014, at
    12:00 p.m. ET, at The Boston Marriott Copley Place hotel in Boston, MA

Live and archived audio webcasts of the company's sessions will be available
on the "Events" section of Intercept's investor website at
http://ir.interceptpharma.com.

About Intercept

Intercept is a biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat orphan and more prevalent
liver and intestinal diseases utilizing its expertise in bile acid chemistry.
The company's lead product candidate, obeticholic acid (OCA), is a bile acid
analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is
being developed for a variety of chronic liver diseases including primary
biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), portal
hypertension, bile acid diarrhea and primary sclerosing cholangitis (PSC). OCA
has received orphan drug designation in both the United States and Europe for
the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside
of Japan and China, where it has out-licensed the product candidate to
Dainippon Sumitomo Pharma. For more information about Intercept, please visit
the Company's website at: www.interceptpharma.com.

CONTACT: For more information about Intercept, please contact
         Barbara Duncan or Senthil Sundaram, both of
         Intercept Pharmaceuticals at 1-646-747-1000.
        
         Media inquiries: media@interceptpharma.com
         Investor inquiries: investors@interceptpharma.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement